Defining EGFR amplification status for clinical trial inclusion

BACKGROUND: Precision medicine trials targeting the epidermal growth factor receptor (EGFR) in glioblastoma patients require selection for EGFR-amplified tumors. However, there is currently no gold standard in determining the amplification status of EGFR or variant III (EGFRvIII) expression. Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales: French, Pim J, Eoli, Marica, Sepulveda, Juan Manuel, de Heer, Iris, Kros, Johan M, Walenkamp, Annemiek, Frenel, Jean-Sebastien, Franceschi, Enrico, Clement, Paul M, Weller, Michael, Ansell, Peter, Looman, Jim, Bain, Earle, Morfouace, Marie, Gorlia, Thierry, van den Bent, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784284/
https://www.ncbi.nlm.nih.gov/pubmed/31125418
http://dx.doi.org/10.1093/neuonc/noz096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784284/
https://www.ncbi.nlm.nih.gov/pubmed/31125418
http://dx.doi.org/10.1093/neuonc/noz096

Ejemplares similares